Are Tolerability Concerns a Class Effect of Beta-Blockers in Treating Patients with Hypertension?

References

• . Rosamond W, Flegal K, Furie K, ; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117(4):e25–e146
   PubMed Web of Science ®Google Scholar
• . Wiysonge CS, Bradley H, Mayosi BM, . Beta-blockers for hypertension. Cochrane Database Syst Rev. 2007(1):CD002003
   Google Scholar
• . Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288(3):351–357
   PubMed Web of Science ®Google Scholar
• . Ubel PA, Jepson C, Asch DA. Misperceptions about beta-blockers and diuretics: a national survey of primary care physicians. J Gen Intern Med. 2003;18(12):977–983
   PubMedGoogle Scholar
• . Leslie WS, Hankey CR, Lean ME. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM. 2007;100(7):395–404
   PubMed Web of Science ®Google Scholar
• . Bradley HA, Wiysonge CS, Volmink JA, Mayosi BM, Opie LH. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens. 2006;24(11):2131–2141
   PubMed Web of Science ®Google Scholar
• . Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297(2):177–186
   PubMed Web of Science ®Google Scholar
• . Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension. 1999;34(4 pt 2):724–728
   PubMed Web of Science ®Google Scholar
• . Packer M. Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog Cardiovasc Dis. 1998;41(1 suppl 1): 39–52
   PubMedGoogle Scholar
• . Lopez-Sendon J, Swedberg K, McMurray J, ; Task Force on Beta-Blockers of the European Society of Cardiology. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J. 2004;25(15):1341–1362
   PubMed Web of Science ®Google Scholar
• . Egan BM, Basile J, Chilton RJ, Cohen JD. Cardioprotection: the role of beta-blocker therapy. J Clin Hypertens (Greenwich). 2005;7(7):409–416
   PubMedGoogle Scholar
• . Frishman WH. A historical perspective on the development of beta-adrenergic blockers. J Clin Hypertens (Greenwich). 2007;9(4 suppl 3): 19–27
   PubMedGoogle Scholar
• . Pedersen ME, Cockcroft JR. The vasodilatory beta-blockers. Curr Hypertens Rep. 2007;9(4):269–277
   PubMed Web of Science ®Google Scholar
• . Ko DT, Hebert PR, Coffey CS, . Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. Arch Intern Med. 2004;164(13):1389–1394
   PubMedGoogle Scholar
• . Hunt SA, Abraham WT, Chin MH, ; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112(12):e154–e235
   PubMed Web of Science ®Google Scholar
• . Fogari R, Zoppi A, Tettamanti F, Poletti L, Rizzardi G, Fiocchi G. Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease. Cardiovasc Drugs Ther. 1990;4(4):1145–1149
   PubMedGoogle Scholar
• . Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM. 2006;99(7):431–436
   PubMedGoogle Scholar
• . American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of hypertension. Endocr Pract. 2006;12(2):193–222
   PubMedGoogle Scholar
• . Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol. 2007;100(8):1254–1262
   PubMed Web of Science ®Google Scholar
• . Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369(9557):201–207
   PubMed Web of Science ®Google Scholar
• . Beeley L. Drug interactions and beta-blockers. Br Med J (Clin Res Ed). 1984;289(6455):1330–1331
   PubMedGoogle Scholar
• . Frishman WH. Beta-adrenergic receptor blockers. Adverse effects and drug interactions. Hypertension. 1988;11(3 pt 2):II21–II29
   PubMedGoogle Scholar
• . Harder S, Thürmann P. Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet. 1996;30(6):416–444
   PubMed Web of Science ®Google Scholar
• . Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B. The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients. Br J Clin Pharmacol. 1984;17( suppl 1):108S–111S
   PubMed Web of Science ®Google Scholar
• . Watkins J, Abbott EC, Hensby CN, Webster J, Dollery CT. Attenuation of hypotensive effect of propranolol and thiazide diuretics by indomethacin. Br Med J. 1980;281(6242):702–705
   PubMedGoogle Scholar
• . Douglas JG, Bakris GL, Epstein M, ; Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003;163(5):525–541
   PubMedGoogle Scholar
• . Ferdinand KC, Armani AM. The management of hypertension in African Americans. Crit Pathw Cardiol. 2007;6(2):67–71
   PubMedGoogle Scholar
• . Cowie CC, Rust KF, Byrd-Holt DD, . Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999–2002. Diabetes Care. 2006;29(6):1263–1268
   PubMed Web of Science ®Google Scholar
• . Messerli FH, Grossman E. Beta-blockers in hypertension: is carvedilol different? Am J Cardiol. 2004;93(9A):7B–12B
   PubMed Web of Science ®Google Scholar
• . George RB, Light RW, Hudson LD, . Comparison of the effects of labetalol and hydrochlorothiazide on the ventilatory function of hypertensive patients with asthma and propranolol sensitivity. Chest. 1985;88(6):815–818
   PubMedGoogle Scholar
• . George RB, Manocha K, Burford JG, Conrad SA, Kinasewitz GT. Effects of labetalol in hypertensive patients with chronic obstructive pulmonary disease. Chest. 1983;83(3):457–460
   PubMedGoogle Scholar
• . Carter BL. Labetalol. Drug Intell Clin Pharm. 1983;17(10):704–712
   PubMedGoogle Scholar
• . Giles TD, Weber M, Bartels DW, . Evaluation of labetalol in elderly patients with essential hypertension. J Clin Pharmacol. 1991;31(6): 556–560
   PubMedGoogle Scholar
• . Toda N. Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol Ther. 2003;100(3):215–234
   PubMedGoogle Scholar
• . Afonso RA, Patarrao RS, Macedo MP, Carmo MM. Carvedilol action is dependent on endogenous production of nitric oxide. Am J Hypertens. 2006;19(4):419–425
   PubMedGoogle Scholar
• . Packer M, Bristow MR, Cohn JN, . The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334(21): 1349–1355
   PubMed Web of Science ®Google Scholar
• . Weber MA, Bakris GL, Tarka EA, Iyengar M, Fleck R, Sica DA. Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. J Clin Hypertens (Greenwich). 2006;8(12):840–849
   PubMedGoogle Scholar
• . Packer M, Fowler MB, Roecker EB, ; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106(17):2194–2199
   PubMed Web of Science ®Google Scholar
• . Poole-Wilson PA, Swedberg K, Cleland JG, . Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7–13
   PubMed Web of Science ®Google Scholar
• . Henderson LS, Tenero DM, Baidoo CA, . Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension. Am J Cardiol. 2006;98(7A):17L–26L
   PubMed Web of Science ®Google Scholar
• . Veverka A, Nuzum DS, Jolly JL. Nebivolol: a third-generation beta-adrenergic blocker. Ann Pharmacother. 2006;40(7–8):1353–1360
   PubMed Web of Science ®Google Scholar
• . Van Bortel LM, Fici F, Mascagni F. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. Am J Cardiovasc Drugs. 2008;8(1):35–44
   PubMed Web of Science ®Google Scholar
• . Czuriga I, Riecansky I, Bodnar J, ; NEBIS Investigators Group. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovasc Drugs Ther. 2003;17(3):257–263
   PubMedGoogle Scholar
• . Grassi G, Trevano FQ, Facchini A, Toutouzas T, Chanu B, Mancia G. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. Blood Press Suppl. 2003;2:35–40
   PubMedGoogle Scholar
• . Rosei EA, Rizzoni D, Comini S, Boari G; Nebivolol-Lisinopril Study Group. Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study. Blood Press Suppl. 2003;1: 30–35
   PubMedGoogle Scholar
• . Uhlir O, Fejfusa M, Havranek K, . Nebivolol versus metoprolol in the treatment of hypertension. Drug Invest. 1991;3( suppl 1):107–110
   Google Scholar
• . Van Bortel LM, Bulpitt CJ, Fici F. Quality of life and antihypertensive effect with nebivolol and losartan. Am J Hypertens. 2005;18(8): 1060–1066
   PubMedGoogle Scholar
• . Van Nueten L, Dupont AG, Vertommen C, Goyvaerts H, Robertson JI. A dose-response trial of nebivolol in essential hypertension. J Hum Hypertens. 1997;11(2):139–144
   PubMedGoogle Scholar
• . Van Nueten L, Lacourciere Y, Vyssoulis G, . Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial. Am J Ther. 1998;5(4):237–243
   PubMedGoogle Scholar
• . Van Nueten L, Schelling A, Vertommen C, Dupont AG, Robertson JI. Nebivolol vs enalapril in the treatment of essential hypertension: a double-blind randomised trial. J Hum Hypertens. 1997;11(12):813–819
   PubMedGoogle Scholar
• . Van Nueten L, Taylor FR, Robertson JI. Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. J Hum Hypertens. 1998;12(2):135–140
   PubMed Web of Science ®Google Scholar
• . Weiss RJ, Weber MA, Carr AA, Sullivan WA. A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension. J Clin Hypertens (Greenwich). 2007;9(9):667–676
   PubMedGoogle Scholar
• . Brixius K, Middeke M, Lichtenthal A, Jahn E, Schwinger RH. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin Exp Pharmacol Physiol. 2007;34(4):327–331
   PubMed Web of Science ®Google Scholar
• . Boydak B, Nalbantgil S, Fici F, . A randomised comparison of the effects of nebivolol and atenolol with and without chlorthalidone on the sexual function of hypertensive men. Clin Drug Investig. 2005;25(6):409–416
   PubMed Web of Science ®Google Scholar
• . Bakris GL, Fonseca V, Katholi RE, . Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292(18):2227–2237
   PubMed Web of Science ®Google Scholar
• . Bakris GL, Hart P, Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int. 2006;70(11):1905–1913
   PubMed Web of Science ®Google Scholar
• . Torp-Pedersen C, Metra M, Charlesworth A, ; COMET Investigators. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart. 2007;93(8):968–973
   PubMedGoogle Scholar
• . Celik T, Iyisoy A, Kursaklioglu H, . Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens. 2006;24(3):591–596
   PubMed Web of Science ®Google Scholar
• . Poirier L, Cléroux J, Nadeau A, Lacourcière Y. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens. 2001;19(8):1429–1435
   PubMed Web of Science ®Google Scholar
• . Flamenbaum W, Weber MA, McMahon FG, Materson BJ, Carr AA, Poland M. Monotherapy with labetalol compared with propranolol. Differential effects by race. J Clin Hypertens. 1985;1(1):56–69
   PubMedGoogle Scholar
• . Saunders E, Smith WB, DeSalvo KB, Sullivan WA. The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens (Greenwich). 2007;9(11):866–875
   PubMedGoogle Scholar
• . Wright JT Jr, Bakris GL, Bell DS, . Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI trial. J Clin Hypertens (Greenwich). 2007;9(11):842–849
   PubMedGoogle Scholar
• . Phillips RA, Fonseca V, Katholi RE, . Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in subjects with type 2 diabetes and hypertension in the GEMINI study. J Cardiometab Syndr. In press.
   Google Scholar
• . Abraham WT, Massie BM, Lukas MA, ; COHERE Participant Physicians. Tolerability, safety, and efficacy of beta-blockade in black patients with heart failure in the community setting: insights from a large prospective beta-blocker registry. Congest Heart Fail. 2007;13(1):16–21
   PubMedGoogle Scholar
• . Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study. JAMA. 1977;237(3):255–261
   PubMedGoogle Scholar
• . Chobanian AV, Bakris GL, Black HR, ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–1252
   PubMed Web of Science ®Google Scholar
• . Antman EM, Hand M, Armstrong PW, . 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society: endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation. 2008;117(2):296–329
   PubMed Web of Science ®Google Scholar
• . Fraker TD Jr, Fihn SD, Gibbons RJ, ; American College of Cardiology; American Heart Association; American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group. 2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina. Circulation. 2007;116(23):2762–2772
   PubMed Web of Science ®Google Scholar
• . National Collaborating Centre for Chronic Conditions. Hypertension: Management of Adults in Primary Care: Pharmacological Update. London, England: Royal College of Physicians; 2006
   Google Scholar
• . Mancia G, De Backer G, Dominiczak A, . 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28(12):1462–1536
   PubMed Web of Science ®Google Scholar